APO Research
Talk to an analyst

APO RESEARCH · REPORT

Chronic Metabolic Disease Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Chronic Metabolic Disease Drug Market Analysis and Forecast 2026-2032

22 December 2025192 pages

Choose your research edition.

Industry ResearchChronic Metabolic Disease Drug Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Chronic Metabolic Disease Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Chronic Metabolic Disease Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Chronic Metabolic Disease Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Chronic Metabolic Disease Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Chronic Metabolic Disease Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Chronic Metabolic Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Chronic Metabolic Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Chronic Metabolic Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Chronic Metabolic Disease Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Chronic Metabolic Disease Drug include Novartis, Novo Nordisk, Merck & Co. Inc, Eli Lilly, Pfizer, GlaxoSmithKline plc, Fresenius Kabi, Daiichi Sankyo and AstraZeneca plc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Chronic Metabolic Disease Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Chronic Metabolic Disease Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Chronic Metabolic Disease Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chronic Metabolic Disease Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Chronic Metabolic Disease Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Chronic Metabolic Disease Drug sales, projected growth trends, production technology, application and end-user industry.

Chronic Metabolic Disease Drug Segment by Company

Novartis

Novo Nordisk

Merck & Co. Inc

Eli Lilly

Pfizer

GlaxoSmithKline plc

Fresenius Kabi

Daiichi Sankyo

AstraZeneca plc

Torrent Labs

Regeneron Pharmaceuticals

Boehringer Ingelheim

Actelion Pharmaceuticals

Chronic Metabolic Disease Drug Segment by Type

Hyperlipidemia Drug

Hypertension Drug

High Blood Sugar Drug

High Uric Acid Drug

Chronic Metabolic Disease Drug Segment by Application

Hospital

Clinic

Others

Chronic Metabolic Disease Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Chronic Metabolic Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Chronic Metabolic Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Chronic Metabolic Disease Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Chronic Metabolic Disease Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Chronic Metabolic Disease Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chronic Metabolic Disease Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Chronic Metabolic Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Hyperlipidemia Drug Major Manufacturers Table 3. Hypertension Drug Major Manufacturers Table 4. High Blood Sugar Drug Major Manufacturers Table 5. High Uric Acid Drug Major Manufacturers Table 6. Global Chronic Metabolic Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Chronic Metabolic Disease Drug Industry Trends Table 11. Chronic Metabolic Disease Drug Industry Drivers Table 12. Chronic Metabolic Disease Drug Industry Opportunities and Challenges Table 13. Chronic Metabolic Disease Drug Industry Restraints Table 14. Global Chronic Metabolic Disease Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Chronic Metabolic Disease Drug Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Chronic Metabolic Disease Drug Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2021-2026) Table 18. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2027-2032) Table 19. Global Chronic Metabolic Disease Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (tons) Table 20. Global Chronic Metabolic Disease Drug Sales by Region (2021-2026) & (tons) Table 21. Global Chronic Metabolic Disease Drug Sales by Region (2027-2032) & (tons) Table 22. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2021-2026) Table 23. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2027-2032) Table 24. Global Chronic Metabolic Disease Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Chronic Metabolic Disease Drug Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Chronic Metabolic Disease Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Chronic Metabolic Disease Drug Sales Market Share by Manufacturers (2021-2026) Table 28. Global Chronic Metabolic Disease Drug Sales Price (US$/ton) of Manufacturers (2021-2026) Table 29. Global Chronic Metabolic Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Chronic Metabolic Disease Drug Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Chronic Metabolic Disease Drug Manufacturers, Product Type & Application Table 32. Global Chronic Metabolic Disease Drug Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Chronic Metabolic Disease Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Chronic Metabolic Disease Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2026) Table 39. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2027-2032) Table 40. Global Chronic Metabolic Disease Drug Sales by Type 2021 VS 2025 VS 2032 (tons) Table 41. Global Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 42. Global Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 43. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2026) Table 44. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2027-2032) Table 45. Global Chronic Metabolic Disease Drug Price by Type (2021-2026) & (US$/ton) Table 46. Global Chronic Metabolic Disease Drug Price by Type (2027-2032) & (US$/ton) Table 47. Global Chronic Metabolic Disease Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2026) Table 51. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2027-2032) Table 52. Global Chronic Metabolic Disease Drug Sales by Application 2021 VS 2025 VS 2032 (tons) Table 53. Global Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 54. Global Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 55. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2026) Table 56. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2027-2032) Table 57. Global Chronic Metabolic Disease Drug Price by Application (2021-2026) & (US$/ton) Table 58. Global Chronic Metabolic Disease Drug Price by Application (2027-2032) & (US$/ton) Table 59. Novartis Company Information Table 60. Novartis Business Overview Table 61. Novartis Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 62. Novartis Chronic Metabolic Disease Drug Product Portfolio Table 63. Novartis Recent Development Table 64. Novo Nordisk Company Information Table 65. Novo Nordisk Business Overview Table 66. Novo Nordisk Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 67. Novo Nordisk Chronic Metabolic Disease Drug Product Portfolio Table 68. Novo Nordisk Recent Development Table 69. Merck & Co. Inc Company Information Table 70. Merck & Co. Inc Business Overview Table 71. Merck & Co. Inc Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 72. Merck & Co. Inc Chronic Metabolic Disease Drug Product Portfolio Table 73. Merck & Co. Inc Recent Development Table 74. Eli Lilly Company Information Table 75. Eli Lilly Business Overview Table 76. Eli Lilly Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 77. Eli Lilly Chronic Metabolic Disease Drug Product Portfolio Table 78. Eli Lilly Recent Development Table 79. Pfizer Company Information Table 80. Pfizer Business Overview Table 81. Pfizer Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 82. Pfizer Chronic Metabolic Disease Drug Product Portfolio Table 83. Pfizer Recent Development Table 84. GlaxoSmithKline plc Company Information Table 85. GlaxoSmithKline plc Business Overview Table 86. GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 87. GlaxoSmithKline plc Chronic Metabolic Disease Drug Product Portfolio Table 88. GlaxoSmithKline plc Recent Development Table 89. Fresenius Kabi Company Information Table 90. Fresenius Kabi Business Overview Table 91. Fresenius Kabi Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 92. Fresenius Kabi Chronic Metabolic Disease Drug Product Portfolio Table 93. Fresenius Kabi Recent Development Table 94. Daiichi Sankyo Company Information Table 95. Daiichi Sankyo Business Overview Table 96. Daiichi Sankyo Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 97. Daiichi Sankyo Chronic Metabolic Disease Drug Product Portfolio Table 98. Daiichi Sankyo Recent Development Table 99. AstraZeneca plc Company Information Table 100. AstraZeneca plc Business Overview Table 101. AstraZeneca plc Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 102. AstraZeneca plc Chronic Metabolic Disease Drug Product Portfolio Table 103. AstraZeneca plc Recent Development Table 104. Torrent Labs Company Information Table 105. Torrent Labs Business Overview Table 106. Torrent Labs Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 107. Torrent Labs Chronic Metabolic Disease Drug Product Portfolio Table 108. Torrent Labs Recent Development Table 109. Regeneron Pharmaceuticals Company Information Table 110. Regeneron Pharmaceuticals Business Overview Table 111. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 112. Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio Table 113. Regeneron Pharmaceuticals Recent Development Table 114. Boehringer Ingelheim Company Information Table 115. Boehringer Ingelheim Business Overview Table 116. Boehringer Ingelheim Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 117. Boehringer Ingelheim Chronic Metabolic Disease Drug Product Portfolio Table 118. Boehringer Ingelheim Recent Development Table 119. Actelion Pharmaceuticals Company Information Table 120. Actelion Pharmaceuticals Business Overview Table 121. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales (tons), Revenue (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 122. Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio Table 123. Actelion Pharmaceuticals Recent Development Table 124. North America Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 125. North America Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 126. North America Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 127. North America Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 128. North America Chronic Metabolic Disease Drug Sales Price by Type (2021-2026) & (US$/ton) Table 129. North America Chronic Metabolic Disease Drug Sales Price by Type (2027-2032) & (US$/ton) Table 130. North America Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 131. North America Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 132. North America Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 133. North America Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 134. North America Chronic Metabolic Disease Drug Sales Price by Application (2021-2026) & (US$/ton) Table 135. North America Chronic Metabolic Disease Drug Sales Price by Application (2027-2032) & (US$/ton) Table 136. North America Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. North America Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 138. North America Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 139. North America Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 140. North America Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 141. North America Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 142. North America Chronic Metabolic Disease Drug Sales Price by Country (2021-2026) & (US$/ton) Table 143. North America Chronic Metabolic Disease Drug Sales Price by Country (2027-2032) & (US$/ton) Table 144. United States Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 145. Canada Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 146. Mexico Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 147. Europe Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 148. Europe Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 149. Europe Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 150. Europe Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 151. Europe Chronic Metabolic Disease Drug Sales Price by Type (2021-2026) & (US$/ton) Table 152. Europe Chronic Metabolic Disease Drug Sales Price by Type (2027-2032) & (US$/ton) Table 153. Europe Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 154. Europe Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 155. Europe Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 156. Europe Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 157. Europe Chronic Metabolic Disease Drug Sales Price by Application (2021-2026) & (US$/ton) Table 158. Europe Chronic Metabolic Disease Drug Sales Price by Application (2027-2032) & (US$/ton) Table 159. Europe Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Europe Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. Europe Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. Europe Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 163. Europe Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 164. Europe Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 165. Europe Chronic Metabolic Disease Drug Sales Price by Country (2021-2026) & (US$/ton) Table 166. Europe Chronic Metabolic Disease Drug Sales Price by Country (2027-2032) & (US$/ton) Table 167. Germany Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 168. France Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 169. U.K. Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 170. Italy Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 171. Russia Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 172. Spain Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 173. Netherlands Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 174. Switzerland Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 175. Sweden Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 176. Poland Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 177. China Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 178. China Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 179. China Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 180. China Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 181. China Chronic Metabolic Disease Drug Sales Price by Type (2021-2026) & (US$/ton) Table 182. China Chronic Metabolic Disease Drug Sales Price by Type (2027-2032) & (US$/ton) Table 183. China Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 184. China Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 185. China Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 186. China Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 187. China Chronic Metabolic Disease Drug Sales Price by Application (2021-2026) & (US$/ton) Table 188. China Chronic Metabolic Disease Drug Sales Price by Application (2027-2032) & (US$/ton) Table 189. Asia Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 190. Asia Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 191. Asia Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 192. Asia Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 193. Asia Chronic Metabolic Disease Drug Sales Price by Type (2021-2026) & (US$/ton) Table 194. Asia Chronic Metabolic Disease Drug Sales Price by Type (2027-2032) & (US$/ton) Table 195. Asia Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 196. Asia Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 197. Asia Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 198. Asia Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 199. Asia Chronic Metabolic Disease Drug Sales Price by Application (2021-2026) & (US$/ton) Table 200. Asia Chronic Metabolic Disease Drug Sales Price by Application (2027-2032) & (US$/ton) Table 201. Asia Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 202. Asia Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 203. Asia Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 204. Asia Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 205. Asia Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 206. Asia Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 207. Asia Chronic Metabolic Disease Drug Sales Price by Country (2021-2026) & (US$/ton) Table 208. Asia Chronic Metabolic Disease Drug Sales Price by Country (2027-2032) & (US$/ton) Table 209. Japan Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 210. South Korea Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 211. India Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 212. Australia Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 213. Taiwan Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 214. Southeast Asia Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 215. SAMEA Chronic Metabolic Disease Drug Revenue by Type (2021-2026) & (US$ Million) Table 216. SAMEA Chronic Metabolic Disease Drug Revenue by Type (2027-2032) & (US$ Million) Table 217. SAMEA Chronic Metabolic Disease Drug Sales by Type (2021-2026) & (tons) Table 218. SAMEA Chronic Metabolic Disease Drug Sales by Type (2027-2032) & (tons) Table 219. SAMEA Chronic Metabolic Disease Drug Sales Price by Type (2021-2026) & (US$/ton) Table 220. SAMEA Chronic Metabolic Disease Drug Sales Price by Type (2027-2032) & (US$/ton) Table 221. SAMEA Chronic Metabolic Disease Drug Revenue by Application (2021-2026) & (US$ Million) Table 222. SAMEA Chronic Metabolic Disease Drug Revenue by Application (2027-2032) & (US$ Million) Table 223. SAMEA Chronic Metabolic Disease Drug Sales by Application (2021-2026) & (tons) Table 224. SAMEA Chronic Metabolic Disease Drug Sales by Application (2027-2032) & (tons) Table 225. SAMEA Chronic Metabolic Disease Drug Sales Price by Application (2021-2026) & (US$/ton) Table 226. SAMEA Chronic Metabolic Disease Drug Sales Price by Application (2027-2032) & (US$/ton) Table 227. SAMEA Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 228. SAMEA Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 229. SAMEA Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 230. SAMEA Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 231. SAMEA Chronic Metabolic Disease Drug Sales by Country (2021-2026) & (tons) Table 232. SAMEA Chronic Metabolic Disease Drug Sales by Country (2027-2032) & (tons) Table 233. SAMEA Chronic Metabolic Disease Drug Sales Price by Country (2021-2026) & (US$/ton) Table 234. SAMEA Chronic Metabolic Disease Drug Sales Price by Country (2027-2032) & (US$/ton) Table 235. Brazil Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 236. Argentina Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 237. Chile Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 238. Colombia Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 239. Peru Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 240. Saudi Arabia Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 241. Israel Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 242. UAE Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 243. Turkey Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 244. Iran Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 245. Egypt Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Table 246. Key Raw Materials Table 247. Raw Materials Key Suppliers Table 248. Chronic Metabolic Disease Drug Distributors List Table 249. Chronic Metabolic Disease Drug Customers List Table 250. Research Programs/Design for This Report Table 251. Authors List of This Report Table 252. Secondary Sources Table 253. Primary Sources List of Figures Figure 1. Chronic Metabolic Disease Drug Image Figure 2. Global Chronic Metabolic Disease Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Chronic Metabolic Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Hyperlipidemia Drug Image Figure 5. Hypertension Drug Image Figure 6. High Blood Sugar Drug Image Figure 7. High Uric Acid Drug Image Figure 8. Global Chronic Metabolic Disease Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Chronic Metabolic Disease Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Chronic Metabolic Disease Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Chronic Metabolic Disease Drug Revenue (2021-2032) & (US$ Million) Figure 15. Global Chronic Metabolic Disease Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Chronic Metabolic Disease Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2021-2032) Figure 18. Global Chronic Metabolic Disease Drug Sales (2021-2032) & (tons) Figure 19. Global Chronic Metabolic Disease Drug Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 20. Global Chronic Metabolic Disease Drug Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Chronic Metabolic Disease Drug Sales YoY (2021-2032) & (tons) Figure 22. Europe Chronic Metabolic Disease Drug Sales YoY (2021-2032) & (tons) Figure 23. China Chronic Metabolic Disease Drug Sales YoY (2021-2032) & (tons) Figure 24. Asia (Excluding China) Chronic Metabolic Disease Drug Sales YoY (2021-2032) & (tons) Figure 25. South America, Middle East and Africa Chronic Metabolic Disease Drug Sales YoY (2021-2032) & (tons) Figure 26. Global Chronic Metabolic Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Chronic Metabolic Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Chronic Metabolic Disease Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Chronic Metabolic Disease Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2032) Figure 32. Global Chronic Metabolic Disease Drug Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 33. Global Chronic Metabolic Disease Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2032) Figure 35. Global Chronic Metabolic Disease Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Chronic Metabolic Disease Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2032) Figure 38. Global Chronic Metabolic Disease Drug Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 39. Global Chronic Metabolic Disease Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2032) Figure 41. North America Chronic Metabolic Disease Drug Revenue Share by Type (2021-2032) Figure 42. North America Chronic Metabolic Disease Drug Sales Share by Type (2021-2032) Figure 43. North America Chronic Metabolic Disease Drug Revenue Share by Application (2021-2032) Figure 44. North America Chronic Metabolic Disease Drug Sales Share by Application (2021-2032) Figure 45. North America Chronic Metabolic Disease Drug Revenue Share by Country (2021-2032) Figure 46. North America Chronic Metabolic Disease Drug Sales Share by Country (2021-2032) Figure 47. Europe Chronic Metabolic Disease Drug Revenue Share by Type (2021-2032) Figure 48. Europe Chronic Metabolic Disease Drug Sales Share by Type (2021-2032) Figure 49. Europe Chronic Metabolic Disease Drug Revenue Share by Application (2021-2032) Figure 50. Europe Chronic Metabolic Disease Drug Sales Share by Application (2021-2032) Figure 51. Europe Chronic Metabolic Disease Drug Revenue Share by Country (2021-2032) Figure 52. Europe Chronic Metabolic Disease Drug Sales Share by Country (2021-2032) Figure 53. China Chronic Metabolic Disease Drug Revenue Share by Type (2021-2032) Figure 54. China Chronic Metabolic Disease Drug Sales Share by Type (2021-2032) Figure 55. China Chronic Metabolic Disease Drug Revenue Share by Application (2021-2032) Figure 56. China Chronic Metabolic Disease Drug Sales Share by Application (2021-2032) Figure 57. Asia Chronic Metabolic Disease Drug Revenue Share by Type (2021-2032) Figure 58. Asia Chronic Metabolic Disease Drug Sales Share by Type (2021-2032) Figure 59. Asia Chronic Metabolic Disease Drug Revenue Share by Application (2021-2032) Figure 60. Asia Chronic Metabolic Disease Drug Sales Share by Application (2021-2032) Figure 61. Asia Chronic Metabolic Disease Drug Revenue Share by Country (2021-2032) Figure 62. Asia Chronic Metabolic Disease Drug Sales Share by Country (2021-2032) Figure 63. SAMEA Chronic Metabolic Disease Drug Revenue Share by Type (2021-2032) Figure 64. SAMEA Chronic Metabolic Disease Drug Sales Share by Type (2021-2032) Figure 65. SAMEA Chronic Metabolic Disease Drug Revenue Share by Application (2021-2032) Figure 66. SAMEA Chronic Metabolic Disease Drug Sales Share by Application (2021-2032) Figure 67. SAMEA Chronic Metabolic Disease Drug Revenue Share by Country (2021-2032) Figure 68. SAMEA Chronic Metabolic Disease Drug Sales Share by Country (2021-2032) Figure 69. Chronic Metabolic Disease Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Chronic Metabolic Disease Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Hyperlipidemia Drug
  • Hypertension Drug
  • High Blood Sugar Drug
  • High Uric Acid Drug
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Novartis
  • Novo Nordisk
  • Merck & Co. Inc
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline plc
  • Fresenius Kabi
  • Daiichi Sankyo
  • AstraZeneca plc
  • Torrent Labs
  • Regeneron Pharmaceuticals
  • Boehringer Ingelheim
  • Actelion Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Chronic Metabolic Disease Drug Market by Type
  3. 1.2.1 Global Chronic Metabolic Disease Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Hyperlipidemia Drug
  5. 1.2.3 Hypertension Drug
  6. 1.2.4 High Blood Sugar Drug
  7. 1.2.5 High Uric Acid Drug
  8. 1.3 Chronic Metabolic Disease Drug Market by Application
  9. 1.3.1 Global Chronic Metabolic Disease Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Chronic Metabolic Disease Drug Market Dynamics
  1. 2.1 Chronic Metabolic Disease Drug Industry Trends
  2. 2.2 Chronic Metabolic Disease Drug Industry Drivers
  3. 2.3 Chronic Metabolic Disease Drug Industry Opportunities and Challenges
  4. 2.4 Chronic Metabolic Disease Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Chronic Metabolic Disease Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Chronic Metabolic Disease Drug Revenue by Region
  3. 3.2.1 Global Chronic Metabolic Disease Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Chronic Metabolic Disease Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Chronic Metabolic Disease Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Chronic Metabolic Disease Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Chronic Metabolic Disease Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Chronic Metabolic Disease Drug Sales by Region
  9. 3.4.1 Global Chronic Metabolic Disease Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Chronic Metabolic Disease Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Chronic Metabolic Disease Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Chronic Metabolic Disease Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Chronic Metabolic Disease Drug Revenue by Manufacturers
  2. 4.1.1 Global Chronic Metabolic Disease Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Chronic Metabolic Disease Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Chronic Metabolic Disease Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Chronic Metabolic Disease Drug Sales by Manufacturers
  6. 4.2.1 Global Chronic Metabolic Disease Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Chronic Metabolic Disease Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Chronic Metabolic Disease Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Chronic Metabolic Disease Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Chronic Metabolic Disease Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Chronic Metabolic Disease Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Chronic Metabolic Disease Drug Manufacturers, Product Type & Application
  13. 4.7 Global Chronic Metabolic Disease Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Chronic Metabolic Disease Drug Market CR5 and HHI
  16. 4.8.2 2025 Chronic Metabolic Disease Drug Tier 1, Tier 2, and Tier 3
5 Chronic Metabolic Disease Drug Market by Type
  1. 5.1 Global Chronic Metabolic Disease Drug Revenue by Type
  2. 5.1.1 Global Chronic Metabolic Disease Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Chronic Metabolic Disease Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Chronic Metabolic Disease Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Chronic Metabolic Disease Drug Sales by Type
  6. 5.2.1 Global Chronic Metabolic Disease Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Chronic Metabolic Disease Drug Sales by Type (2021-2032) & (tons)
  8. 5.2.3 Global Chronic Metabolic Disease Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Chronic Metabolic Disease Drug Price by Type
6 Chronic Metabolic Disease Drug Market by Application
  1. 6.1 Global Chronic Metabolic Disease Drug Revenue by Application
  2. 6.1.1 Global Chronic Metabolic Disease Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Chronic Metabolic Disease Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Chronic Metabolic Disease Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Chronic Metabolic Disease Drug Sales by Application
  6. 6.2.1 Global Chronic Metabolic Disease Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Chronic Metabolic Disease Drug Sales by Application (2021-2032) & (tons)
  8. 6.2.3 Global Chronic Metabolic Disease Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Chronic Metabolic Disease Drug Price by Application
7 Company Profiles
  1. 7.1 Novartis
  2. 7.1.1 Novartis Company Information
  3. 7.1.2 Novartis Business Overview
  4. 7.1.3 Novartis Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Novartis Chronic Metabolic Disease Drug Product Portfolio
  6. 7.1.5 Novartis Recent Developments
  7. 7.2 Novo Nordisk
  8. 7.2.1 Novo Nordisk Company Information
  9. 7.2.2 Novo Nordisk Business Overview
  10. 7.2.3 Novo Nordisk Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Novo Nordisk Chronic Metabolic Disease Drug Product Portfolio
  12. 7.2.5 Novo Nordisk Recent Developments
  13. 7.3 Merck & Co. Inc
  14. 7.3.1 Merck & Co. Inc Company Information
  15. 7.3.2 Merck & Co. Inc Business Overview
  16. 7.3.3 Merck & Co. Inc Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co. Inc Chronic Metabolic Disease Drug Product Portfolio
  18. 7.3.5 Merck & Co. Inc Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly Chronic Metabolic Disease Drug Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Chronic Metabolic Disease Drug Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 GlaxoSmithKline plc
  32. 7.6.1 GlaxoSmithKline plc Company Information
  33. 7.6.2 GlaxoSmithKline plc Business Overview
  34. 7.6.3 GlaxoSmithKline plc Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 GlaxoSmithKline plc Chronic Metabolic Disease Drug Product Portfolio
  36. 7.6.5 GlaxoSmithKline plc Recent Developments
  37. 7.7 Fresenius Kabi
  38. 7.7.1 Fresenius Kabi Company Information
  39. 7.7.2 Fresenius Kabi Business Overview
  40. 7.7.3 Fresenius Kabi Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Fresenius Kabi Chronic Metabolic Disease Drug Product Portfolio
  42. 7.7.5 Fresenius Kabi Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Chronic Metabolic Disease Drug Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 AstraZeneca plc
  50. 7.9.1 AstraZeneca plc Company Information
  51. 7.9.2 AstraZeneca plc Business Overview
  52. 7.9.3 AstraZeneca plc Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 AstraZeneca plc Chronic Metabolic Disease Drug Product Portfolio
  54. 7.9.5 AstraZeneca plc Recent Developments
  55. 7.10 Torrent Labs
  56. 7.10.1 Torrent Labs Company Information
  57. 7.10.2 Torrent Labs Business Overview
  58. 7.10.3 Torrent Labs Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Torrent Labs Chronic Metabolic Disease Drug Product Portfolio
  60. 7.10.5 Torrent Labs Recent Developments
  61. 7.11 Regeneron Pharmaceuticals
  62. 7.11.1 Regeneron Pharmaceuticals Company Information
  63. 7.11.2 Regeneron Pharmaceuticals Business Overview
  64. 7.11.3 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Regeneron Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
  66. 7.11.5 Regeneron Pharmaceuticals Recent Developments
  67. 7.12 Boehringer Ingelheim
  68. 7.12.1 Boehringer Ingelheim Company Information
  69. 7.12.2 Boehringer Ingelheim Business Overview
  70. 7.12.3 Boehringer Ingelheim Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Boehringer Ingelheim Chronic Metabolic Disease Drug Product Portfolio
  72. 7.12.5 Boehringer Ingelheim Recent Developments
  73. 7.13 Actelion Pharmaceuticals
  74. 7.13.1 Actelion Pharmaceuticals Company Information
  75. 7.13.2 Actelion Pharmaceuticals Business Overview
  76. 7.13.3 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Actelion Pharmaceuticals Chronic Metabolic Disease Drug Product Portfolio
  78. 7.13.5 Actelion Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Chronic Metabolic Disease Drug Market Size by Type
  2. 8.1.1 North America Chronic Metabolic Disease Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Chronic Metabolic Disease Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Chronic Metabolic Disease Drug Price by Type (2021-2032)
  5. 8.2 North America Chronic Metabolic Disease Drug Market Size by Application
  6. 8.2.1 North America Chronic Metabolic Disease Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Chronic Metabolic Disease Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Chronic Metabolic Disease Drug Price by Application (2021-2032)
  9. 8.3 North America Chronic Metabolic Disease Drug Market Size by Country
  10. 8.3.1 North America Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Chronic Metabolic Disease Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Chronic Metabolic Disease Drug Market Size by Type
  2. 9.1.1 Europe Chronic Metabolic Disease Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Chronic Metabolic Disease Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Chronic Metabolic Disease Drug Price by Type (2021-2032)
  5. 9.2 Europe Chronic Metabolic Disease Drug Market Size by Application
  6. 9.2.1 Europe Chronic Metabolic Disease Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Chronic Metabolic Disease Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Chronic Metabolic Disease Drug Price by Application (2021-2032)
  9. 9.3 Europe Chronic Metabolic Disease Drug Market Size by Country
  10. 9.3.1 Europe Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Chronic Metabolic Disease Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Chronic Metabolic Disease Drug Market Size by Type
  2. 10.1.1 China Chronic Metabolic Disease Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Chronic Metabolic Disease Drug Sales by Type (2021-2032)
  4. 10.1.3 China Chronic Metabolic Disease Drug Price by Type (2021-2032)
  5. 10.2 China Chronic Metabolic Disease Drug Market Size by Application
  6. 10.2.1 China Chronic Metabolic Disease Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Chronic Metabolic Disease Drug Sales by Application (2021-2032)
  8. 10.2.3 China Chronic Metabolic Disease Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Chronic Metabolic Disease Drug Market Size by Type
  2. 11.1.1 Asia Chronic Metabolic Disease Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Chronic Metabolic Disease Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Chronic Metabolic Disease Drug Price by Type (2021-2032)
  5. 11.2 Asia Chronic Metabolic Disease Drug Market Size by Application
  6. 11.2.1 Asia Chronic Metabolic Disease Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Chronic Metabolic Disease Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Chronic Metabolic Disease Drug Price by Application (2021-2032)
  9. 11.3 Asia Chronic Metabolic Disease Drug Market Size by Country
  10. 11.3.1 Asia Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Chronic Metabolic Disease Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Chronic Metabolic Disease Drug Market Size by Type
  2. 12.1.1 SAMEA Chronic Metabolic Disease Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Chronic Metabolic Disease Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Chronic Metabolic Disease Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Chronic Metabolic Disease Drug Market Size by Application
  6. 12.2.1 SAMEA Chronic Metabolic Disease Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Chronic Metabolic Disease Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Chronic Metabolic Disease Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Chronic Metabolic Disease Drug Market Size by Country
  10. 12.3.1 SAMEA Chronic Metabolic Disease Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Chronic Metabolic Disease Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Chronic Metabolic Disease Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Chronic Metabolic Disease Drug Value Chain Analysis
  2. 13.1.1 Chronic Metabolic Disease Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Chronic Metabolic Disease Drug Production Mode & Process
  6. 13.2 Chronic Metabolic Disease Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Chronic Metabolic Disease Drug Distributors
  9. 13.2.3 Chronic Metabolic Disease Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst